vimarsana.com

Page 132 - ஒன்றுபட்டது மாநிலங்களில் பத்திரங்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Judge allows Ripple to depose SEC official who decided ETH is not a security

Judge allows Ripple to depose SEC official who decided ETH is not a security Bill Hinman could be called to testify on his 2018 comments regarding Ethereum’s security status. 41576 Total views News San-Francisco-based fintech firm Ripple has notched up another small victory in its ongoing battle with the United States Securities and Exchange Commission. U.S. District Court Judge Sarah Netburn has denied the SEC’s motion to suppress the deposition of the former director of the SEC’s Division of Corporation Finance, William Hinman, in a ruling in New York on Thursday. In June 2018, Hinman said in a speech that based on his understanding of the Ethereum network and its decentralized structure, the “current offers and sales of Ether are not securities transactions.”

Petroteq Announces Expected Late Filing of Financial Statements and Application for Management Cease Trade Order; Cautions Against Reliance on Certain Previously-Issued Financial Statements

Petroteq Announces Expected Late Filing of Financial Statements and Application for Management Cease Trade Order; Cautions Against Reliance on Certain Previously-Issued Financial Statements ACCESSWIRE SHERMAN OAKS, CA / ACCESSWIRE / July 16, 2021 / Petroteq Energy Inc. ( Petroteq or the Company ) ‎‎(TSXV:PQE) ‎(OTC PINK:PQEFF)(FSE:PQCF), an integrated oil ‎company focused on the development and implementation of its proprietary oil-‎extraction and remediation technologies, cautions that, on July 16, 2021, the independent members of the Audit Committee (with Mr. Alex Blyumkin abstaining, the Audit Committee ) of the Board of Directors of the Company (the Board ), after discussion with the Company s Chief Financial Officer, concluded that:

Lilly and Incyte provide update on supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis

Press release content from PR Newswire. The AP news staff was not involved in its creation. Lilly and Incyte provide update on supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis July 16, 2021 GMT INDIANAPOLIS, July 16, 2021 /PRNewswire/ Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) will not meet the Prescription Drug User Fee Act (PDUFA) action date for the supplemental new drug application (sNDA) for baricitinib for the treatment of adults with moderate to severe atopic dermatitis (AD). The delay is related to the FDA’s ongoing assessment of JAK inhibitors.

US SEC Pushes WisdomTree Bitcoin ETF Decision to Fall

US SEC Pushes WisdomTree Bitcoin ETF Decision to Fall
entrepreneur.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from entrepreneur.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.